Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy Treatment for Triple Negative Breast Cancer
Elizabeth R. Berger, Tristen Park, Angeleke Saridakis, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 8, pp. 763-763
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
Chenyi Luo, Peipei Wang, Siqi He, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 98
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer
Alessandro Rizzo, Antonio Cusmai, Silvana Acquafredda, et al.
Future Oncology (2022) Vol. 18, Iss. 18, pp. 2301-2309
Closed Access | Times Cited: 50
Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs
André E. Nel, Kuo‐Ching Mei, Yu‐Pei Liao, et al.
ACS Nano (2022) Vol. 16, Iss. 4, pp. 5184-5232
Open Access | Times Cited: 45
Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?
Emma E. Newton, Lauren Mueller, Scout Treadwell, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 482-482
Open Access | Times Cited: 41
Functionalized siRNA-chitosan nanoformulations promote triple-negative breast cancer cell death via blocking the miRNA-21/AKT/ERK signaling axis: in-silico and in vitro studies
Shaymaa A. Abdulmalek, Abdulrahman M. Saleh, Yasmin R. Shahin, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 9, pp. 6941-6962
Open Access | Times Cited: 8
The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer
Lin He, Neda Wick, Sharon Koorse Germans, et al.
Cancers (2021) Vol. 13, Iss. 24, pp. 6209-6209
Open Access | Times Cited: 45
Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer
Abygail G. Chapdelaine, Gongqin Sun
Biomolecules (2023) Vol. 13, Iss. 8, pp. 1207-1207
Open Access | Times Cited: 21
New Achievements for the Treatment of Triple-Negative Breast Cancer
Alessia Catalano, Domenico Iacopetta, Jessica Ceramella, et al.
Applied Sciences (2022) Vol. 12, Iss. 11, pp. 5554-5554
Open Access | Times Cited: 24
Natural products as part of triple negative breast cancer
Yozlem Kobakova, Maria Moneva-Sakelarieva, Spiro Konstantinov, et al.
Pharmacia (2025) Vol. 72, pp. 1-11
Open Access
Novel triazoloquinazoline derivatives as VEGFR inhibitors: synthesis, cytotoxic evaluation and in silico studies
Reda R. Mabrouk, Hazem A. Mahdy, Abdallah E. Abdallah, et al.
Future Medicinal Chemistry (2025), pp. 1-13
Closed Access
Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation
Chenxing Zhang, Jiaxin Liu, Tiejun Gu, et al.
Breast Cancer Research and Treatment (2025)
Closed Access
Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer
Maryam Nakhjavani, Sarah Shigdar
Pharmacological Research (2021) Vol. 175, pp. 106019-106019
Closed Access | Times Cited: 31
Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer
Kassidy M. Jungles, Erin A. Holcomb, Ashley N. Pearson, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 22
Dual Anticancer and Antibacterial Properties of Silica-Based Theranostic Nanomaterials Functionalized with Coumarin343, Folic Acid and a Cytotoxic Organotin(IV) Metallodrug
Maider Ugalde-Arbizu, John Jairo Aguilera-Correa, Victoria García‐Almodóvar, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 560-560
Open Access | Times Cited: 11
Recent Developments in Combination Immunotherapy with Other Therapies and Nanoparticle-Based Therapy for Triple-Negative Breast Cancer (TNBC)
Gantumur Battogtokh, Onyinyechi Obidiro, Emmanuel O. Akala
Cancers (2024) Vol. 16, Iss. 11, pp. 2012-2012
Open Access | Times Cited: 4
An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer
Asma Jan, Shazia Sofi, Nusrat Jan, et al.
Future Oncology (2025), pp. 1-21
Closed Access
Interleukin-6 Signaling in Triple Negative Breast Cancer Cells Elicits the Annexin A1/Formyl Peptide Receptor 1 Axis and Affects the Tumor Microenvironment
Lara Vecchi, Sara Teixeira Soares Mota, Mariana Alves Pereira Zóia, et al.
Cells (2022) Vol. 11, Iss. 10, pp. 1705-1705
Open Access | Times Cited: 16
Design, Synthesis, and Anti-Breast Cancer Potential of Imidazole–Pyridine Hybrid Molecules In Vitro and Ehrlich Ascites Carcinoma Growth Inhibitory Activity Assessment In Vivo
Baladhandapani Aruchamy, Mahadevaswamy G. Kuruburu, Venugopal R. Bovilla, et al.
ACS Omega (2023) Vol. 8, Iss. 43, pp. 40287-40298
Open Access | Times Cited: 10
Gex2SGen: Designing Drug-like Molecules from Desired Gene Expression Signatures
Dibyajyoti Das, Broto Chakrabarty, Rajgopal Srinivasan, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 7, pp. 1882-1893
Closed Access | Times Cited: 9
Acidic/hypoxia dual-alleviated nanoregulators for enhanced treatment of tumor chemo-immunotherapy
Xiaoju Guo, Xiaoxiao Chen, Jiayi Ding, et al.
Asian Journal of Pharmaceutical Sciences (2024) Vol. 19, Iss. 2, pp. 100905-100905
Open Access | Times Cited: 3
The cross-talk of autophagy and apoptosis in breast carcinoma: implications for novel therapies?
Kamil Seyrek, Fabian Wohlfromm, Johannes Espe, et al.
Biochemical Journal (2022) Vol. 479, Iss. 14, pp. 1581-1608
Closed Access | Times Cited: 13
Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer
Xingyu Li, Yanyan Zhang, Cheng Zhu, et al.
BMC Women s Health (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer
Hikmat Abdel‐Razeq, Hanan Khalil, Hazem Assi, et al.
Current Oncology (2022) Vol. 29, Iss. 8, pp. 5810-5822
Open Access | Times Cited: 12
Comprehensive analysis of PTPN gene family revealing PTPN7 as a novel biomarker for immuno-hot tumors in breast cancer
Fengxu Wang, Xuehai Wang, Lei Liu, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 12
Calorie restriction and breast cancer treatment: a mini-review
Meden F. Isaac-Lam, Kelly DeMichael
Journal of Molecular Medicine (2022) Vol. 100, Iss. 8, pp. 1095-1109
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top